Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Modulation of the human IgE response

J E de Vries1, H Yssel

  • 1Human Immunology Dept, DNAX Research Institute for Molecular and Cellular Biology, Palo Alto, CA, USA.

The European Respiratory Journal. Supplement
|August 1, 1996
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Editorial Expression of Concern: The X-linked lymphoproliferative-disease gene product SAP regulates signals induced through the co-receptor SLAM.

Nature·2026
Same author

Guidelines for Lyme borreliosis: treatment.

Infectious diseases now·2025
Same author

Guidelines for tick-borne diseases (excluding Lyme borreliosis): diagnosis and management.

Infectious diseases now·2025
Same author

Pillars Article: The X-Linked Lymphoproliferative Disease Gene Product SAP Regulates Signals Induced through the Co-Receptor SLAM. <i>Nature</i>. 1998. 395: 462-469.

Journal of immunology (Baltimore, Md. : 1950)·2017
Same author

Excellent prognosis of node negative patients after sentinel node procedure in colon carcinoma: a 5-year follow-up study.

European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology·2013
Same author

Characterization of intratumoral follicular helper T cells in follicular lymphoma: role in the survival of malignant B cells.

Leukemia·2011

Novel therapies targeting allergic diseases focus on inhibiting interleukin-4 (IL-4) and interleukin-13 (IL-13) to reduce immunoglobulin E (IgE) production. A modified IL-4 protein (IL-4,Y124D) and allergen-specific T-cell anergy show promise in controlling IgE synthesis.

Area of Science:

  • Immunology
  • Allergy Research
  • Cytokine Signaling

Background:

  • Allergic diseases are linked to elevated interleukin-4 (IL-4) and interleukin-13 (IL-13) production and reduced interferon-gamma (IFN-gamma) by T-cells.
  • This imbalance promotes immunoglobulin E (IgE) synthesis, a key factor in allergic reactions.
  • Inhibiting IL-4 and IL-13 is a potential strategy to manage IgE-mediated allergies.

Purpose of the Study:

  • To explore novel therapeutic approaches for inhibiting IgE production in allergic diseases.
  • To investigate the efficacy of a novel IL-4 mutant protein (IL-4,Y124D) as an antagonist.
  • To examine the potential of inducing T-helper 2 (Th2) cell anergy for immunotherapy.

Main Methods:

  • Developed and tested an IL-4 mutant protein (IL-4,Y124D) for its ability to bind the IL-4 receptor without activation.

Related Experiment Videos

  • Assessed the antagonist activity of IL-4,Y124D against IL-4 and IL-13 in vitro, measuring effects on immunoglobulin G4 (IgG4) and IgE production.
  • Induced anergy in allergen-specific Th2 cells via incubation with allergen-derived peptides and evaluated their subsequent cytokine production, proliferation, and B-cell help for IgE synthesis.

    • Main Results:

    • IL-4,Y124D demonstrated high-affinity binding to the IL-4 receptor and acted as a potent antagonist of IL-4 and IL-13, inhibiting IgG4 and IgE production.
    • Anergized Th2 cells failed to produce IL-4 and IL-13, proliferate, or provide help for IgE synthesis, despite normal CD40 ligand expression.
    • Exogenous IL-2 restored the nonresponsive state and helper function of anergized T-cells, indicating the requirement for IL-2-mediated co-stimulatory signals for IgE synthesis.

    Conclusions:

    • The IL-4 mutant IL-4,Y124D shows promise as a therapeutic agent by blocking IL-4 and IL-13 signaling pathways.
    • Inducing allergen-specific Th2 cell anergy through peptide-based immunotherapy may be a viable strategy for treating allergic diseases.
    • Successful immunotherapy might rely on inducing T-cell nonresponsiveness, potentially reversing allergic conditions.